Anavex Life Sciences has reported noteworthy progress in the treatment of Alzheimer’s disease with their investigational therapy, blarcamesine. During a recent Phase 2b/3 trial, the therapy demonstrated substantial reductions in amyloid-ß biomarkers, a critical indicator of Alzheimer’s pathology, sparking optimism in the scientific community.  The study was a multicenter, randomized, double-blind, placebo-controlled trial involving 508 […]